Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
SEVERE ALLERGIC REACTIONS
ODACTRA tablets contain house dust mite allergen extract from Dermatophagoides farinae and Dermatophagoides pteronyssinus. ODACTRA is a sublingual tablet that dissolves within 10 seconds.
ODACTRA is available as a tablet of 12 SQ-HDM [6 SQ-HDM D. farinae and 6 SQ-HDM D. pteronyssinus]. Each tablet contains a 1:1:1:1 potency ratio of D. farinae group 1 allergen, D. farinae group 2 allergen, D. pteronyssinus group 1 allergen, and D. pteronyssinus group 2 allergen.
Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.
ODACTRA™ is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in persons 12 through 65 years of age.
ODACTRA is not indicated for the immediate relief of allergic symptoms.
For sublingual use only.
One ODACTRA tablet daily.
Administer the first dose of ODACTRA in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. After receiving the first dose of ODACTRA, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home. The patient should administer ODACTRA as follows:
Data regarding the safety of restarting treatment after missing a dose of ODACTRA are limited. In the clinical studies, treatment interruptions for up to seven days were allowed.
Prescribe auto-injectable epinephrine to patients prescribed ODACTRA and instruct patients (or their parents/guardians) in the proper use of auto-injectable epinephrine [see WARNINGS AND PRECAUTIONS].
ODACTRA is available as 12 SQ-HDM* tablets that are white to off-white, circular with a debossed pentagon detail on one side.
*SQ-HDM is the dose unit for ODACTRA. SQ is a method of standardization of biological potency, major allergen content and complexity of the allergen extract. HDM is an abbreviation for house dust mite.
ODACTRA 12 SQ-HDM tablets are white to off-white, circular freeze-dried sublingual tablets with a debossed pentagon detail on one side.
ODACTRA is supplied as follows:
3 blister packages of 10 tablets (30 tablets total). NDC 52709-1701-3
Store at controlled room temperature, 20°C-25°C (68°F-77°F). Store in the original package until use to protect from moisture.
Manufactured for: ALK-Abello A/S, ALK-Abello A/S, Boge Alle 6-8, DK-2970 Horsholm, Denmark. Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK. Revised: Jan 2023
The most common solicited adverse reactions reported in ≥10% of adult subjects (18 through 65 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, tongue pain, nausea, throat swelling, stomach pain, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and food tastes different. The most common solicited adverse reactions reported in ≥10% of adolescent subjects (12 through 17 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, and mouth ulcer/sore in the mouth, and diarrhea.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In four double-blind, placebo-controlled, randomized clinical studies, a total of 1279 subjects with house dust mite-induced allergic rhinitis, with or without conjunctivitis, 18 through 65 years of age was treated with at least one dose of ODACTRA 12 SQ-HDM. Of subjects treated with ODACTRA in the four studies, 50% had mild to moderate asthma and 71% were polysensitized to other allergens in addition to HDM, including trees, grasses, weeds, molds, and animal danders. The study population was 88% White, 6% African American, 4% Asian and 55% female.
Study 1 (NCT01700192) was a randomized, double-blind, placebo-controlled study conducted in the US and Canada evaluating ODACTRA in 1482 subjects 12 years of age and older with house dust mite-induced allergic rhinitis with or without conjunctivitis. Of the 1482 subjects, 640 subjects 18 through 65 years of age received at least one dose of ODACTRA, with a median treatment duration of 267 days (range 1 to 368 days). 631 subjects received placebo. Placebo tablets contained the same inactive ingredients as ODACTRA without allergen extract and were packaged identically so that treatment blind/masking was maintained. Participants were monitored for unsolicited adverse events and serious adverse events (SAEs) for the duration of therapy (up to 52 weeks). Participants were monitored for solicited adverse reactions for the first 28 days following treatment initiation.
Study participants were provided side effect report cards in which they recorded the occurrence of specific solicited adverse reactions daily for the first 28 days following treatment initiation with ODACTRA or placebo. In Study 1, the most common solicited adverse reactions reported in ≥10% of subjects treated with ODACTRA were: throat irritation/tickle (67.0% vs. 20.8% placebo), itching in the mouth (61.3% vs. 14.1%), itching in the ear (51.7% vs. 11.7%), swelling of the uvula/back of the mouth (19.8% vs. 2.4%), swelling of the lips (18.0% vs. 2.7%), swelling of the tongue (15.8% vs. 2.1%), nausea (14.2% vs. 7.1%), tongue pain (14.2% vs. 3.0%), throat swelling (13.6% vs. 2.4%), tongue ulcer/sore on the tongue (11.6% vs. 2.1%), stomach pain (11.3% vs. 5.2%), mouth ulcer/sore in the mouth (10.3% vs. 2.9%), and taste alteration/food tastes different (10.0% vs. 3.6%). Table 1 summarizes all solicited adverse reactions reported within the first 28 days of treatment initiation in subjects 18 through 65 years of age using the patient-friendly term.
Table 1: Solicited* Adverse Reactions Within 28 Days After Initiation of Treatment with ODACTRA or Placebo (Study 1, Safety Analysis Set) in Subjects 18 through 65 Years of Age (NCT01700192)
| Adverse Reaction | Any Intensity | Severe† | ||
| ODACTRA (N=640) |
Placebo (N=631) |
ODACTRA (N=640) |
Placebo (N=631) |
|
| Ear and labyrinth disorders | ||||
| Itching in the ear | 51.7% | 11.7% | 0.3% | - |
| Gastrointestinal disorders | ||||
| Itching in the mouth | 61.3% | 14.1% | 0.2% | - |
| Swelling of the uvula/back of the mouth‡ | 19.8% | 2.4% | - | - |
| Swelling of the lips | 18.0% | 2.7% | - | - |
| Swelling of the tongue | 15.8% | 2.1% | - | - |
| Nausea | 14.2% | 7.1% | - | - |
| Tongue pain | 14.2% | 3.0% | - | - |
| Tongue ulcer/sore on the tongue | 11.6% | 2.1% | - | - |
| Stomach pain | 11.3% | 5.2% | 0.2% | - |
| Mouth ulcer/sore in the mouth | 10.3% | 2.9% | - | - |
| Diarrhea | 6.9% | 3.6% | - | - |
| Vomiting | 2.5% | 1.4% | - | - |
| Nervous system disorders | ||||
| Taste alteration/food tastes different | 10.0% | 3.6% | - | - |
| Respiratory, thoracic and mediastinal disorders | ||||
| Throat irritation/tickle | 67.0% | 20.8% | 0.3% | - |
| Throat swelling | 13.6% | 2.4% | 0.2% | - |
| In Table 1, the dashes represent no subjects. *Solicited adverse reactions (modified from World Allergy Organization [WAO] list of local side effects of sublingual immunotherapy [SLIT]) were those reported by subjects within the first 28 days after treatment initiation. †Severe adverse reactions were those assessed by the investigator as severe in intensity, which is defined as incapacitating with inability to work or do usual activity. ‡The percentage of subjects reported for the patient-friendly term of “swelling of the uvula/back of the mouth” includes subjects with an enlarged uvula, palatal swelling/edema, and/or mouth swelling/edema (which can be anywhere in the mouth, not specifically back of the mouth). |
||||
In Study 1, the timing of the adverse reaction relative to exposure to ODACTRA was evaluated for 7 solicited adverse reactions (itching in the ear, itching in the mouth, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat irritation/tickle, and throat swelling). The median time to onset of these adverse reactions following initiation of treatment with ODACTRA varied from 1 to 7 days. The median duration of these adverse reactions that occurred on the first day of treatment initiation varied from 30 to 60 minutes. These adverse reactions recurred for a median of 2 to 12 days.
In Study 1, the following unsolicited adverse events were reported in numerically more subjects treated with ODACTRA than with placebo and occurred in ≥1% of subjects 18 through 65 years of age within 28 days after initiation of treatment with ODACTRA: paresthesia oral (9.2% vs. 3.2%), tongue pruritus (4.7% vs. 1.1%), oral pain (2.7% vs. 0.6%), stomatitis (2.5% vs. 1.1%), dyspepsia (2.2% vs. 0.0%), pharyngeal erythema (2.0% vs. 0.3%), eye pruritus (1.7% vs. 1.4%), oral mucosal erythema (1.7% vs. 0.2%), upper respiratory tract infection (1.6% vs. 1.1%), sneezing (1.6% vs. 0.3%), lip pruritus (1.4% vs. 0.3%), dysphagia (1.4% vs. 0.0%), fatigue (1.3% vs. 1.0%), hypoesthesia oral (1.3% vs. 1.0%), oropharyngeal pain (1.3% vs. 0.6%), chest discomfort (1.3% vs. 0.3%), dry throat (1.3% vs. 0.3%), pruritus (1.1% vs. 1.0%), and urticaria (1.1% vs. 0.3%).
Studies 2 (NCT01454544) and 3 (NCT01644617) were randomized, double-blind, placebo-controlled studies of subjects 18 years of age and older with house dust mite-induced allergic rhinitis with or without conjunctivitis, and with or without asthma. Study 4 (NCT01433523) was a randomized, double-blind placebo-controlled study that included subjects 18 years of age and older with house dust mite-induced asthma and allergic rhinitis, with or without conjunctivitis.
Across the four clinical studies, 1279 subjects received at least one dose of ODACTRA, of whom 1104 (86%) completed at least 4 months of therapy.
The percentages of subjects in these studies who discontinued treatment because of an adverse reaction while exposed to ODACTRA or placebo were 8.1% and 3.0%, respectively. The most common adverse reactions (≥1.0%) that led to study discontinuation in subjects who received ODACTRA were throat irritation (1.5%), oral pruritus (1.3%), ear pruritus (1.1%), and mouth swelling (1.0%).
Serious adverse events were reported, 16/1279 (1.3%) among ODACTRA recipients and 23/1277 (1.8%) among placebo recipients. No deaths were reported.
Epinephrine use was reported in 5/1279 (0.4%) subjects who received ODACTRA compared to 3/1277 (0.2%) of subjects who received placebo. Of these subjects, 1 ODACTRA recipient reported a systemic allergic reaction and used epinephrine on the day of treatment initiation compared to 2 placebo recipients who reported anaphylaxis and used epinephrine 6 and 25 days after treatment initiation, respectively.
Of 1279 subjects who received ODACTRA, 34 (2.7%) reported dyspepsia compared to 0/1277 (0%) of subjects who received placebo. Twenty subjects who received ODACTRA (1.6%) reported symptoms of gastroesophageal reflux disease (GERD) compared to 3/1277 (0.2%) of subjects who received placebo.
In two clinical studies, a total of 347 adolescent subjects were treated with at least one dose of ODACTRA. Study 1 (NCT01700192) was a double-blind, placebo-controlled, randomized clinical study. Study 5 (NCT04541004) was a single arm, open-label safety study. Because the study design and safety data presentation differ in the studies, adverse reaction rates cannot be directly compared. Overall, the safety profile in adolescents was consistent with the safety profile in adults.
Study 1 was a randomized, double-blind, placebo-controlled study conducted in the US and Canada evaluating ODACTRA in 1482 subjects 12 years of age and older with house dust mite-induced allergic rhinitis with or without conjunctivitis. Of the 1482 subjects, 94 subjects 12 through 17 years of age received at least one dose of ODACTRA, with a median treatment duration of 279 days (range 1 to 353 days). 95 subjects received placebo. Of the adolescent subjects treated with ODACTRA, 53% were male, 39% had asthma, and 72% were polysensitized to other allergens in addition to HDM. The adolescent subject population was 69% White, 13% Black or African American, 10% multiple race, 5% Asian, and 3% American Indian or Alaska Native. Subject demographics in placebo-treated subjects were similar to the active treatment group.
In Study 1, study participants were provided side effect report cards in which they recorded the occurrence of specific solicited adverse reactions daily for the first 28 days following treatment initiation with ODACTRA or placebo. The solicited adverse reactions reported in adolescent subjects 12 through 17 years of age are summarized in Table 2.
Table 2: Solicited* Adverse Reactions Within 28 Days After Initiation of Treatment with ODACTRA or Placebo (Study 1, Safety Analysis Set) in Subjects 12 through 17 Years of Age (NCT01700192)
| Adverse Reaction (Any Intensity‡) | ODACTRA (N=94) |
Placebo (N=95) |
| Ear and labyrinth disorders | ||
| Itching in the ear | 50.0% | 11.6% |
| Gastrointestinal disorders | ||
| Itching in the mouth‡ | 73.4% | 14.7% |
| Tongue pain | 24.5% | 4.2% |
| Stomach pain | 23.4% | 15.8% |
| Swelling of the uvula/back of the mouth† | 20.2% | 3.2% |
| Swelling of the lips | 20.2% | 1.1% |
| Swelling of the tongue | 19.1% | 3.2% |
| Nausea‡ | 17.0% | 9.5% |
| Tongue ulcer/sore on the tongue | 12.8% | 4.2% |
| Mouth ulcer/sore in the mouth | 10.6% | 3.2% |
| Diarrhea | 7.7% | 2.1% |
| Vomiting‡ | 4.3% | - |
| Nervous system disorders | ||
| Taste alteration/food tastes different | 4.3% | 4.2% |
| Respiratory, thoracic and mediastinal disorders | ||
| Throat irritation/tickle‡ | 73.4% | 35.8% |
| Throat swelling | 18.1% | 8.4% |
| In Table 2, the dashes represent no subjects. *Solicited adverse reactions (modified from World Allergy Organization [WAO] list of local side effects of sublingual immunotherapy [SLIT]) were those reported by subjects within the first 28 days after treatment initiation. †The percentage of subjects reported for the patient-friendly term of “swelling of the uvula/back of the mouth” includes subjects with an enlarged uvula, palatal swelling, and/or mouth swelling/edema (which can be anywhere in the mouth, not specifically back of the mouth). ‡Of those subjects reporting any intensity of: itching in the mouth, nausea, throat irritation/tickle, or vomiting in the ODACTRA group, 1 subject (1.1%) reported severe intensity of the reaction. Adverse reactions were categorized as severe according to the definition ‘incapacitating with inability to work or do usual activity’, as assessed by the investigator. |
||
In Study 1, participants were monitored for unsolicited adverse events and serious adverse events (SAEs) for the duration of treatment (up to 52 weeks). Unsolicited adverse events that were reported in numerically more subjects treated with ODACTRA than with placebo and occurred in ≥1% of subjects 12 through 17 years of age within 28 days after initiation of treatment with ODACTRA aresummarized in Table 3.
In Study 1, 94 adolescent subjects received at least one dose of ODACTRA, of whom 81 (86%) completed at least 4 months of treatment.
The percentage of adolescent subjects who discontinued from the study because of an adverse reaction while exposed to ODACTRA or placebo was 10% and 1%, respectively. The most common adverse reaction that led to study discontinuation in adolescent subjects who were exposed to ODACTRA were throat irritation (4%), swollen tongue (2%) and nausea (2%).
No adolescent subjects treated with ODACTRA in Study 1 reported serious adverse events, treatment-related systemic allergic reactions, or adverse reactions treated with epinephrine.
Table 3: Unsolicited Adverse Reactions occurring During the Entire Trial After Initiation of Treatment with ODACTRA or Placebo (Study 1, Safety Analysis Set) Reported in ≥1% of Subjects 12 through 17 Years of Age (NCT01700192)
| Adverse Reaction | ODACTRA (N=94)† |
Placebo (N=95)† |
| Ear and labyrinth disorders | ||
| Ear discomfort | 1.1% | - |
| Ear pain | 1.1% | - |
| Eye disorders | ||
| Eye pruritus | 1.1% | - |
| Eye swelling | 1.1% | - |
| Gastrointestinal disorders | ||
| Paraesthesia oral | 5.3% | - |
| Oral pain | 4.3% | - |
| Tongue pruritus | 3.2% | - |
| Stomatitis | 2.1% | 1.1% |
| Aphthous ulcer | 1.1% | - |
| Dysphagia | 1.1% | - |
| Eosinophilic esophagitis | 1.1% | - |
| Salivary gland enlargement | 1.1% | - |
| Tongue discomfort | 1.1% | - |
| General disorders and administration site conditions | ||
| Chest discomfort | 2.1% | - |
| Chest pain | 1.1% | - |
| Non-cardiac chest pain | 1.1% | - |
| Infections and infestations | ||
| Acute sinusitis | 1.1% | - |
| Musculoskeletal and connective tissue disorders | ||
| Arthralgia | 1.1% | - |
| Neck pain | 1.1% | - |
| Respiratory, thoracic and mediastinal disorders | ||
| Oropharyngeal pain | 1.1% | - |
| Rhinorrhea | 1.1% | - |
| Throat tightness | 1.1% | - |
| Tonsillar hypertrophy | 1.1% | - |
| Skin and subcutaneous tissue disorders | ||
| Pruritus | 2.1% | 1.1% |
| Vascular disorders | ||
| Flushing | 1.1% | - |
| In Table 3, the dashes represent no subjects. † Due to the population size (ODACTRA; N=94; and placebo; N=95), 1.1% represents one subject. |
||
Study 5 was a single-arm, open label study conducted in Europe, and exposed 253 subjects 12 through 17 years of age with house dust mite-induced allergic rhinitis with or without conjunctivitis and with or without asthma to at least one dose of ODACTRA. The median treatment duration was 28 days (range 11 to 32 days). Of the subjects, 60% were male, 43% had asthma, and 56% were polysensitized to other allergens in addition to HDM. The subject population was 99.6% White and 0.4% Native Hawaiian or Other Pacific Islander.
Study participants were provided side effect report cards in which they recorded the occurrence of specific solicited adverse reactions daily for the first 28 days following treatment initiation with ODACTRA or placebo. Participants were monitored for unsolicited adverse events and serious adverse events (SAEs) for the duration of the study.
In Study 5, the proportions of subjects reporting solicited adverse reactions during the first 28 days following initiation of treatment with ODACTRA were comparable to those reported during the first 28 days following initiation of treatment with ODACTRA in Study 1.
In Study 5, the following unsolicited adverse reactions occurred in ≥1% of subjects 12 through 17 years of age during the entire study [median treatment duration 28 days (range 11 to 32 days)] after initiation of treatment with ODACTRA: oral pain (3.2%), oral pruritus (2.8%), throat irritation (1.6%), ear pruritus (1.2%), and mouth ulceration (1.2%).
In Study 5, 253 adolescent subjects received at least one dose of ODACTRA, of whom 248 (98%) completed 28 days of treatment. The percentage of subjects who discontinued from the study because of an adverse reaction while exposed to ODACTRA was 1%.
No adolescent subjects in Study 5 reported serious adverse events, treatment-related systemic allergic reactions, or adverse reactions treated with epinephrine.
Across eight clinical studies of varying durations which enrolled individuals 5 through 85 years of age and which were conducted with different doses of ODACTRA, eosinophilic esophagitis was reported in 2/2737 (0.07%) subjects who received ODACTRA compared to 0/1636 (0%) subjects who received placebo. Of these eight clinical studies, 2416 subjects received different doses of ODACTRA in four clinical studies with durations of 12 months or longer [2 cases/2416 subjects (0.08%) who received ODACTRA for 12 months or longer]. One case of eosinophilic esophagitis assessed as related to treatment occurred on Day 99 in an adult subject receiving ODACTRA. One case of eosinophilic esophagitis assessed as related to treatment occurred on Day 204 in an adolescent subject receiving ODACTRA.
The following adverse reactions have been identified during post-approval use of ODACTRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
No Information provided
Included as part of the PRECAUTIONS section.
ODACTRA can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, ODACTRA can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening.
Allergic reactions may require treatment with epinephrine. Prescribe auto-injectable epinephrine to patients receiving ODACTRA. Instruct patients or their parents/guardians to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency auto-injectable epinephrine. Instruct patients or their parents/guardians to seek immediate medical care and to stop treatment with ODACTRA upon use of auto-injectable epinephrine [see Patient Counseling Information] See Prescribing Information for epinephrine for complete information.
ODACTRA may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or that may increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute); severe mast cell disorder; or cardiovascular disease including unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. In addition, ODACTRA may not be suitable for patients who are taking medications that can potentiate or inhibit the effects of epinephrine (see Prescribing Information for epinephrine for information on drug interactions).
Administer the initial dose of ODACTRA in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of ODACTRA.
ODACTRA can cause local reactions in the mouth or throat that could compromise the upper airway [see ADVERSE REACTIONS]. Consider discontinuation of ODACTRA in patients who experience persistent and escalating adverse reactions in the mouth or throat.
Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see CONTRAINDICATIONS)]. Discontinue ODACTRA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastroesophageal symptoms including dysphagia or chest pain.
Withhold immunotherapy with ODACTRA if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ODACTRA.
ODACTRA has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
Stop treatment with ODACTRA to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery or dental extraction.
Advise patients (or their parents/guardians) to read the FDA-approved patient labeling (Medication Guide) and to keep ODACTRA and all medicines out of the reach of children.
ODACTRA has not been evaluated for carcinogenic potential or impairment of fertility in animals. Two in vitro chromosome aberration assays, an in vitro bacterial mutagenesis assay and a combined in vivo Comet and micronucleus assay for mutagenicity in rats were performed using HDM (D. farinae and D. pteronyssinus) allergen extracts. One in vitro chromosome aberration assay was positive. Based on the aggregated results, the weight of evidence indicates that this finding is unlikely to be of clinical relevance.
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on ODACTRA administered to pregnant women are insufficient to inform associated risks in pregnancy.
In an embryo/fetal developmental toxicity study performed in mice, administration of ODACTRA during gestation did not reveal adverse developmental outcomes in fetuses (see Data).
Animal Data
In a developmental toxicity study, the effect of ODACTRA on embryo/fetal development was evaluated in mice. Animals were administered ODACTRA subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose. There were no ODACTRA-related post-implantation losses, fetal malformations or variations.
It is not known whether ODACTRA is excreted in human milk. Data are not available to assess the effects of ODACTRA on the breastfed child or on milk production and excretion in the nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ODACTRA and any potential adverse effects on the breastfed child from ODACTRA or from the underlying maternal condition.
The safety and effectiveness of ODACTRA have been established in adolescents 12 through 17 years of age. The safety and effectiveness have not been established in persons below 12 years of age.
Safety and effectiveness have not been established in persons older than 65 years of age.
Symptoms of overdose may include hypersensitivity reactions such as systemic allergic reactions or severe local allergic reactions [see WARNINGS AND PRECAUTIONS]. In case of severe adverse reactions such as angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, or feeling of fullness in the throat, immediate medical evaluation is needed. These reactions should be treated as medically indicated, including the use of epinephrine as appropriate [see WARNINGS AND PRECAUTIONS].
ODACTRA is contraindicated in patients with:
The precise mechanisms of action of allergen immunotherapy have not been fully established.
The efficacy of ODACTRA for the treatment of HDM-induced allergic rhinitis was investigated in two double-blind, placebo-controlled, randomized clinical field efficacy studies (Studies 1 and 2) and one environmental exposure chamber (EEC) study.
Study 1 (North American Field Efficacy Study)
Study 1 was a double-blind, placebo-controlled, randomized field efficacy study conducted in the United States and Canada for a duration of up to 12 months, that compared the efficacy of ODACTRA (N=741) compared to placebo (N=741) in the treatment of HDM-induced allergic rhinitis. Subjects 12 through 85 years of age were enrolled if they had a history of symptomatic allergic rhinitis and were sensitized to D. farinae and/or D. pteronyssinus as determined by house dust mite specific IgE. Subjects were required to be symptomatic and were not taking symptom-relieving allergy medications at enrollment.
Subjects with mild to moderate asthma, defined as asthma of a severity that required, at most, a daily medium dose of an inhaled corticosteroid, were enrolled in the study.
In this study, 31% of subjects had asthma, 48% had conjunctivitis, and 76% were polysensitized to other allergens in addition to HDM, including trees, grasses, weed, animal danders and molds. The subject population was 76% White, 11% African American, 7% Asian, and 59% female. The mean age of subjects was 35 years.
The efficacy of ODACTRA in the treatment of HDM-induced allergic rhinitis was assessed through self-reporting of symptoms and medication use. Based on these self-assessments, the Total Combined Rhinitis Score (TCRS), daily symptom scores (DSS) and daily medication scores (DMS) for rhinoconjunctivitis were calculated. Daily symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose) and two ocular symptoms (gritty/itchy eyes and watery eyes). Each of these rhinoconjunctivitis symptoms was individually graded by subjects daily on a scale of 0 (none) to 3 (severe) and then summed. Subjects in active and placebo arms of this study were allowed to take symptom-relieving allergy medications (including oral and ocular antihistamines and nasal corticosteroids) during the study as needed. The DMS measured the use of these standard symptom-relieving allergy medications. Predefined daily maximum scores were assigned to each class of rhinitis and conjunctivitis medication as 0=none, 6=oral antihistamine, 6=ocular antihistamine, and 8=nasal corticosteroid.
The primary endpoint was the difference between the treatment and placebo groups in the average TCRS during approximately the last 8 weeks of treatment. The TCRS represents the sum of the daily rhinitis DSS and the rhinitis DMS. Other secondary endpoints in this study included the average rhinitis DSS, the average rhinitis DMS, and the Total Combined Score (TCS). The TCS represents the sum of the rhinoconjunctivitis DSS and the rhinoconjunctivitis DMS, which was then averaged during approximately the last 8 weeks of treatment.
Subjects in this study were required to stop taking symptom-relieving allergy medication during the baseline period. The mean rhinitis DSS at baseline was 7.94 out of 12 total points in both the treatment arm and in the placebo arm. The results of this study are shown in Table 5. Consistent results across age groups were observed, supporting a similar treatment effect in adolescent and adult subgroups.
Table 5: Total Combined Rhinitis Score (TCRS), Rhinitis Daily Symptom Score (DSS), Rhinitis Daily Medication Score (DMS), and Total Combined Score (TCS) During the Last 8 Weeks of Treatment with ODACTRA in Subjects 12 Years of Age and Older (Study 1, Field Efficacy Study) (NCT: NCT01700192)
| Endpoint* | ODACTRA (n=566)† Score‡ |
Placebo (n=620)† Score‡ |
Treatment Difference (ODACTRA- Placebo) | Difference Relative to Placebo§ Estimate (95% CI) |
| Primary Endpoint | ||||
| TCRS¶ | 4.10 | 4.95 | -0.80 | -17.2% (-25.0%, -9.7%) |
| Secondary Endpoints | ||||
| Rhinitis DSS | 3.55 | 4.20 | -0.60 | -15.5% (-24.4%, -7.3%) |
| Rhinitis DMS | 0.65 | 0.79 | -0.15 | -18.4% (-41.0%, 4.3%) |
| TCS | 5.50 | 6.60 | -1.10 | -16.7% (-24.6%, -4.0%) |
| TCRS=Total Combined Rhinitis Score (Rhinitis DSS + Rhinitis DMS); TCS=Total Combined Score (Rhinoconjunctivitis DSS + Rhinoconjunctivitis DMS); CI=Confidence Interval Analyses were based on the full analysis set (FAS), which included all randomized and treated subjects. Subjects were analyzed according to the treatment group to which they were randomized. *Non-parametric analysis for TCRS, Rhinitis DSS, and TCS endpoints; Parametric analysis using zero-inflated log-normal model for Rhinitis DMS endpoint. †Number of subjects in analyses. ‡For TCRS, Rhinitis DSS, and TCS endpoints, the estimated group medians are reported. Treatment difference and that relative to placebo is based on estimated group medians. For Rhinitis DMS, the estimated group means are reported. Treatment difference and that relative to placebo is based on estimated group means. §Difference relative to placebo computed as: (ODACTRA – placebo)/placebo x 100. ¶The pre-specified criteria for demonstration of efficacy was defined as a TCRS difference relative to placebo less than or equal to -15 percent, and the upper bound of the 95 percent confidence interval (CI) of TCRS difference relative to placebo less than or equal to -10 percent. |
||||
Study 2 (European Field Efficacy Study)
This double-blind, placebo-controlled, randomized field efficacy study evaluated adult subjects 18 through 66 years of age comparing ODACTRA (N=318) and placebo (N=338) administered as a sublingual tablet daily for a duration of approximately 12 months. Subjects in this study had a history of symptomatic allergic rhinitis when exposed to house dust and were sensitized to D. farinae and/or D. pteronyssinus as determined by house dust mite specific IgE testing. At study entry, subjects were required to be symptomatic despite taking symptom-relieving allergy medications during the baseline period.
In this study, 46% of subjects had asthma, 97% had conjunctivitis and 67% were polysensitized to other allergens in addition to HDM, including trees, grass, weeds, animal danders and molds. The study population was 98% White, <1% African American, and <1% Asian; 50% of subjects were female. The mean age of subjects in this study was 32 years. The primary efficacy endpoint was the difference relative to placebo in the average TCRS during the last 8 weeks of treatment. The mean Rhinitis DSS at baseline was 7.95 out of 12 for the treatment arm and 8.00 out of 12 total points for the placebo arm. The results of this study are shown in Table 6.
Table 6: Total Combined Rhinitis Score (TCRS), Rhinitis Daily Symptom Score (DSS), Rhinitis Daily Medication Score (DMS), and Total Combined Score (TCS) During the Last 8 Weeks of Treatment with ODACTRA in Subjects 18 Years of Age and Older (Study 2, European Field Efficacy Study) (NCT01454544)
| Endpoint* | ODACTRA (n)† Score‡ | Placebo (n)† Score‡ | Treatment Difference (ODACTRA-Placebo) | Difference Relative to Placebo§ Estimate (95% CI) |
| Primary Endpoint | ||||
| TCRS¶ | (318) 5.71 | (338) 6.81 | -1.09 | -16.1% (-25.8%, -5.7%) |
| Secondary Endpoints | ||||
| Rhinitis DSS¶ | (318) 2.84 | (338) 3.31 | -0.47 | -14.1% (-23.8%, -3.9%) |
| Rhinitis DMS¶ | (318) 2.32 | (338) 2.86 | -0.54 | -18.9% (-34.7%, -1.3%) |
| TCS# | (241) 7.91 | (257) 9.12 | -1.21 | -13.2% (-23.7%, -1.5%) |
| TCRS=Total Combined Rhinitis Score (Rhinitis DSS + Rhinitis DMS); TCS=Total Combined Score (Rhinoconjunctivitis DSS + Rhinoconjunctivitis DMS); CI=Confidence Interval *Parametric analysis using analysis of covariance model for all endpoints. †Number of subjects in analyses. ‡The estimated group least squares means are reported. Treatment difference and that relative to placebo is based on estimated group least squares means. §Difference relative to placebo computed as: (ODACTRA – placebo)/placebo x 100. ¶Analysis based on FAS-MI: full analysis set with multiple imputations. The analysis treats subjects who discontinued the study before the efficacy assessment period as placebo subjects. For the primary analysis (FAS-MI) only the absolute difference was pre-specified. Additional analyses describing the corresponding pre-specified relative differences to placebo for the full analysis set (FAS): TCRS: -18.1% (-27.6%, -7.7%); rhinitis DSS: -16.2% (-25.7%, -5.8%); and rhinitis DMS: -21.4% (-36.6%, -3.2%). #Subjects from Serbia and Croatia were excluded from the analysis of TCS because the preferred formulations of antihistamine eyedrops were not available in these countries at the time the study was conducted. The TCS analysis is based on the full analysis set (FAS). All available data used to its full extent, i.e. subjects who provided data during the efficacy assessment period. |
||||
This double-blind, placebo-controlled, randomized EEC study evaluated adult subjects 18 through 58 years of age comparing ODACTRA (N=42) and placebo (N=41) administered as a sublingual tablet daily for approximately 24 weeks. Subjects had a history of symptomatic allergic rhinitis and were sensitized to D. farinae and/or D. pteronyssinus as determined by HDM specific IgE. In this study, 23% of subjects had asthma, 87% had conjunctivitis, and 84% were polysensitized to other allergens in addition to HDM, including tree, grass, weed, animal danders and molds. The subject population was 90% White, <1% African American, 8% Asian, and 43% female. The mean age of subjects was 27 years.
The primary endpoint was the difference relative to placebo in the average TNSS at Week 24. The Total Nasal Symptom Score (TNSS) represents the sum of 4 nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose). Secondary endpoints were the differences relative to placebo in the average TNSS at Weeks 8 and 16 and average Total Symptom Score (TSS) at Week 24, which represents the sum of TNSS plus 2 ocular symptoms (gritty/itchy eyes and watery eyes). Baseline TNSS following house dust mite EEC challenge prior to treatment was 7.74 out of 12 total points for ODACTRA and 7.32 out of 12 total points for placebo. The results of this study are shown in Table 7.
Table 7: Total Nasal Symptom Score (TNSS) and Total Symptom Score (TSS) During HDM-Allergen Challenge (Study 3, Environmental Exposure Chamber Study) (NCT01644617)
| Endpoint* | ODACTRA (n)† Score‡ | Placebo (n)† Score‡ | Treatment Difference (ODACTRA -Placebo) | Difference Relative to Placebo§ Estimate (95% CI) |
| Primary Endpoint | ||||
| TNSS - Week 24 | (36) 3.83 | (34) 7.45 | -3.62 | -48.6% (-60.2%, -35.3%) |
| Secondary Endpoints | ||||
| TNSS - Week 8 | (40) 5.34 | (39) 6.71 | -1.37 | -20.4% (-33.3%, -6.8%) |
| TNSS - Week 16 | (39) 4.82 | (38) 6.90 | -2.08 | -30.1% (-42.3%, -16.8%) |
| TSS - Week 24 | (36) 4.43 | (34) 9.27 | -4.84 | -52.2% (-65.0%, -37.0%) |
| TNSS=Total Nasal Symptom Score; TSS=Total Symptom Score (TNSS + total ocular symptom score); CI=Confidence Interval *Parametric analysis using analysis of covariance for all endpoints. †Number of subjects in analyses. ‡The estimated group least squares means are reported. Treatment difference and that relative to placebo is based on estimated group least squares means. §Difference relative to placebo computed as: (ODACTRA – placebo)/placebo x 100. |
||||
No information provided. Please refer to the WARNINGS AND PRECAUTIONS section.
